Related Experiment Videos

The current state of beta blockers in hypertension therapy

Joel A Lardizabal1, Prakash C Deedwania

  • 1Division of Cardiology, University of California in San Francisco School of Medicine, Fresno Medical Education Program, Fresno, CA, USA.

Indian Heart Journal
|December 25, 2010
PubMed

Insights

Beta blockers remain effective for hypertension, particularly newer agents in young and diabetic patients. Despite past concerns, cardioselective and vasodilating beta blockers offer improved efficacy and safety for first-line antihypertensive therapy.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • Beta-adrenergic blockers (beta blockers) are established treatments for ischemic heart disease, heart failure, coronary artery disease, and arrhythmias.
  • The efficacy of traditional beta blockers in uncomplicated hypertension has been debated due to comparative cardiovascular outcomes.
  • Recent evidence suggests cardioselective agents are as effective as other drug classes for hypertension.

Purpose of the Study:

  • To re-evaluate the role of beta blockers in contemporary hypertension management.
  • To assess the efficacy and relevance of both traditional and newer-generation beta blockers.
  • To determine the suitability of beta blockers as a first-line antihypertensive therapy.

Main Methods:

  • Review of clinical trial data and established guidelines on beta blocker use in hypertension.
  • Comparative analysis of cardiovascular outcomes between beta blockers and other antihypertensive drug classes.
  • Evaluation of hemodynamic and metabolic profiles of different beta blocker generations.

Main Results:

  • While traditional agents like atenolol have declined in use for hypertension, cardioselective beta blockers demonstrate comparable efficacy to other drug classes.
  • Newer-generation vasodilating beta blockers exhibit favorable hemodynamic, metabolic, and side effect profiles, enhancing their efficacy.
  • Beta blockers are particularly beneficial in young and diabetic individuals with high sympathetic tone and renin levels.

Conclusions:

  • Cardioselective and newer-generation vasodilating beta blockers are effective and viable first-line options for hypertension treatment.
  • The use of beta blockers in hypertension therapy should be continued, especially in specific patient populations.
  • Advancements in beta blocker pharmacology support their continued role in managing uncomplicated hypertension.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...